NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $682,236 | +18.6% | 821,972 | +0.0% | 0.00% | – |
| Q1 2023 | $575,165 | +100.9% | 821,665 | +46.1% | 0.00% | – |
| Q4 2022 | $286,273 | -24.5% | 562,423 | -5.1% | 0.00% | – |
| Q3 2022 | $379,000 | -40.9% | 592,461 | -4.9% | 0.00% | – |
| Q2 2022 | $641,000 | -49.7% | 622,892 | -8.1% | 0.00% | – |
| Q1 2022 | $1,274,000 | -55.9% | 678,120 | +13.0% | 0.00% | – |
| Q4 2021 | $2,891,000 | -33.1% | 600,003 | +0.4% | 0.00% | -100.0% |
| Q3 2021 | $4,321,000 | -25.8% | 597,508 | -5.3% | 0.00% | 0.0% |
| Q2 2021 | $5,824,000 | +36.8% | 631,008 | +82.5% | 0.00% | 0.0% |
| Q1 2021 | $4,256,000 | -29.9% | 345,671 | -19.7% | 0.00% | 0.0% |
| Q4 2020 | $6,067,000 | +163.0% | 430,284 | +123.8% | 0.00% | – |
| Q3 2020 | $2,307,000 | +86.8% | 192,228 | +158.5% | 0.00% | – |
| Q2 2020 | $1,235,000 | +74.7% | 74,369 | +19.6% | 0.00% | – |
| Q1 2020 | $707,000 | +2180.6% | 62,162 | +2397.5% | 0.00% | – |
| Q4 2019 | $31,000 | +520.0% | 2,489 | +25.2% | 0.00% | – |
| Q3 2019 | $5,000 | – | 1,988 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,291,133 | $1,166,187 | 1.01% |
| Privium Fund Management (UK) Ltd | 117,200 | $59,655 | 0.04% |
| Redmile Group, LLC | 1,850,566 | $941,938 | 0.04% |
| Baker Brothers Advisors | 3,821,740 | $1,945,266 | 0.01% |
| Kynam Capital Management, LP | 120,764 | $61,469 | 0.01% |
| Sio Capital Management, LLC | 38,312 | $19,501 | 0.01% |
| SIMON QUICK ADVISORS, LLC | 46,856 | $23,850 | 0.00% |
| Tri Locum Partners LP | 10,248 | $5,000 | 0.00% |
| Endurance Wealth Management, Inc. | 20,000 | $10 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 75,000 | $38,175 | 0.00% |